Published in Br J Cancer on August 01, 1975
Aryl-2-halogenoalkylamines. XXVI. Glucuronic, sulphuric and phosphoric esters of p-di-2-chloroethylaminophenol. Biochem Pharmacol (1972) 1.16
Enzyme activated anti-tumour agents. Conjugates of p-hydroxyaniline mustard as substrates for hydrolytic enzymes. Biochem Pharmacol (1974) 1.07
Guidelines for the welfare and use of animals in cancer research. Br J Cancer (2010) 6.97
DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90. J Natl Cancer Inst (1999) 3.07
The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations. Br J Cancer (2005) 2.85
Reductase enzyme expression across the National Cancer Institute Tumor cell line panel: correlation with sensitivity to mitomycin C and EO9. J Natl Cancer Inst (1996) 2.20
Estimation of the hypoxic cell-sensitiser misonidazole and its O-demethylated metabolite in biological materials by reversed-phase high-performance liquid chromatography. J Chromatogr (1978) 2.08
Characterization of a transplantable adenocarcinoma of the mouse colon producing cachexia in recipient animals. J Natl Cancer Inst (1987) 2.02
Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin results in cytostasis and apoptosis. Cancer Res (2001) 1.86
Transplantation of adenocarcinomas of the colon in mice. J Natl Cancer Inst (1975) 1.85
Direct measurement of pO2 distribution and bioreductive enzymes in human malignant brain tumors. Int J Radiat Oncol Biol Phys (1994) 1.84
DT-diaphorase and cancer chemotherapy. Biochem Pharmacol (1992) 1.78
Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development? J Natl Cancer Inst (1999) 1.70
A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days. Br J Cancer (2006) 1.66
Partition coefficient as a guide to the development of radiosensitizers which are less toxic than misonidazole. Radiat Res (1980) 1.64
Personalized cancer medicine: molecular diagnostics, predictive biomarkers, and drug resistance. Clin Pharmacol Ther (2012) 1.60
9-Alkyl, morpholinyl anthracyclines in the circumvention of multidrug resistance. Eur J Cancer (1990) 1.59
Chemotherapy of transplanted adenocarcinomas of the colon in mice. Cancer Chemother Rep (1976) 1.59
Transplantable colon tumors as chemotherapy screening models. Cancer (1975) 1.55
Establishment and characterisation of cell lines from patients with lung cancer (predominantly small cell carcinoma). Br J Cancer (1985) 1.52
Estimation and identification of thiols in rat spleen after cysteine or glutathione treatment: relevance to protection against nitrogen mustards. Biochem Pharmacol (1966) 1.48
Factors involved in the anti-cancer activity of the investigational agents LM985 (flavone acetic acid ester) and LM975 (flavone acetic acid). Br J Cancer (1987) 1.47
The effect of methylazoxymethanol acetate on DNA synthesis and cell proliferation of synchronous HeLa cells. Mutat Res (1972) 1.46
Progress in the preclinical discovery and clinical development of class I and dual class I/IV phosphoinositide 3-kinase (PI3K) inhibitors. Curr Med Chem (2011) 1.44
Pharmacokinetic considerations in testing hypoxic cell radiosensitizers in mouse tumours. Br J Cancer (1979) 1.42
A critical appraisal of the predictive value of in vitro chemosensitivity assays. J Natl Cancer Inst (1990) 1.38
Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperone. Oncogene (2000) 1.34
Examination by laser scanning confocal fluorescence imaging microscopy of the subcellular localisation of anthracyclines in parent and multidrug resistant cell lines. Br J Cancer (1993) 1.34
Phenytoin shortens the half-life of the hypoxic cell radiosensitizer misonidazole in man: implications for possible reduced toxicity. Br J Cancer (1980) 1.33
Modification of CCNU pharmacokinetics by misonidazole--a major mechanism of chemosensitization in mice. Br J Cancer (1983) 1.33
The role of NAD(P)H: quinone reductase (EC 1.6.99.2, DT-diaphorase) in the reductive bioactivation of the novel indoloquinone antitumor agent EO9. Cancer Commun (1991) 1.32
Reduction of tumor blood flow by flavone acetic acid: a possible component of therapy. J Natl Cancer Inst (1989) 1.31
Monitoring salivary misonidazole in man: a possible alternative to plasma monitoring. Br J Cancer (1978) 1.29
Angiogenesis in the hollow fiber tumor model influences drug delivery to tumor cells: implications for anticancer drug screening programs. Cancer Res (1998) 1.29
A chemical inhibitor of PPM1D that selectively kills cells overexpressing PPM1D. Oncogene (2007) 1.27
Assessment of antiangiogenic and antivascular therapeutics using MRI: recommendations for appropriate methodology for clinical trials. Br J Radiol (2003) 1.27
Gene expression microarray analysis in cancer biology, pharmacology, and drug development: progress and potential. Biochem Pharmacol (2001) 1.24
Silencing the cochaperone CDC37 destabilizes kinase clients and sensitizes cancer cells to HSP90 inhibitors. Oncogene (2008) 1.24
Pharmacokinetics and anti-tumour activity of LM985 in mice bearing transplantable adenocarcinomas of the colon. Br J Cancer (1986) 1.24
Effects of pretreatment with phenobarbitone and phenytoin on the pharmacokinetics and toxicity of phenytoin on the pharmacokinetics and toxicity of misonidazole in mice. Br J Cancer (1979) 1.23
Some biological characteristics of transplantable lines of mouse adenocarcinomas of the colon. J Natl Cancer Inst (1980) 1.21
Hsp90 inhibitors in the clinic. Handb Exp Pharmacol (2006) 1.21
Targeting heat shock protein 72 enhances Hsp90 inhibitor-induced apoptosis in myeloma. Leukemia (2010) 1.19
Discovering novel chemotherapeutic drugs for the third millennium. Eur J Cancer (1999) 1.17
Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns. Leukemia (2012) 1.16
Inhibition of telomerase activity by cisplatin in human testicular cancer cells. Eur J Cancer (1997) 1.15
Structure-pharmacokinetic relationships for misonidazole analogues in mice. Cancer Chemother Pharmacol (1981) 1.14
Molecular enzymology of the reductive bioactivation of hypoxic cell cytotoxins. Int J Radiat Oncol Biol Phys (1989) 1.13
Synthesis and antitumour activity of new derivatives of flavone-8-acetic acid (FAA). Part 3: 2-Heteroaryl derivatives. Arch Pharm (Weinheim) (1998) 1.13
EO9: a novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical models. Eur J Cancer (1993) 1.13
Insulin reversal of diabetes-induced inhibition of vascular contractility in the rat. Am J Physiol (1982) 1.13
An investigation of the possibility of chemosensitization by clinically achievable concentrations of misonidazole. Br J Cancer (1983) 1.11
In vitro activity of the novel indoloquinone EO-9 and the influence of pH on cytotoxicity. Br J Cancer (1992) 1.11
A novel method for measuring incorporation of radioactive precursors into nucleic acids and proteins of cells in monolayer culture. Anal Biochem (1972) 1.10
Clinical studies with misonidazole. Br J Cancer Suppl (1978) 1.10
Pharmacokinetics of hypoxic cell radiosensitizers: a review. Cancer Clin Trials (1980) 1.09
Pharmacokinetic and tumour-penetration properties of the hypoxic cell radiosensitizer desmethylmisonidazole (Ro 05-Ro-9963) in dogs. Br J Cancer (1980) 1.08
Enzyme activated anti-tumour agents. Conjugates of p-hydroxyaniline mustard as substrates for hydrolytic enzymes. Biochem Pharmacol (1974) 1.07
Preclinical pharmacokinetics and metabolism of a novel prototype DNA-PK inhibitor NU7026. Br J Cancer (2005) 1.07
Pharmacokinetics of the hypoxic cell cytotoxic agent tirapazamine and its major bioreductive metabolites in mice and humans: retrospective analysis of a pharmacokinetically guided dose-escalation strategy in a phase I trial. Cancer Chemother Pharmacol (1997) 1.07
A Phase I study of the angiogenesis inhibitor SU5416 (semaxanib) in solid tumours, incorporating dynamic contrast MR pharmacodynamic end points. Br J Cancer (2005) 1.07
Is body composition an important variable in the pharmacokinetics of anticancer drugs? A review and suggestions for further research. Cancer Chemother Pharmacol (1994) 1.06
Drug metabolism and chemosensitization. Nitroimidazoles as inhibitors of drug metabolism. Biochem Pharmacol (1983) 1.06
From darkness to light with biomarkers in early clinical trials of cancer drugs. Clin Pharmacol Ther (2009) 1.06
Retention of activity by selected anthracyclines in a multidrug resistant human large cell lung carcinoma line without P-glycoprotein hyperexpression. Br J Cancer (1991) 1.06
Unusually marked hypoxic sensitization to indoloquinone EO9 and mitomycin C in a human colon-tumour cell line that lacks DT-diaphorase activity. Int J Cancer (1994) 1.04
Comparison of nitrogen-mustard sensitive and -resistant Yoshida sarcomas. Int J Cancer (1966) 1.03
Anti-tumour activity of flavone acetic acid (NSC 347512) in mice--influence of immune status. Br J Cancer (1991) 1.03
Dose-dependence and related studies on the pharmacokinetics of misonidazole and desmethylmisonidazole in mice. Cancer Chemother Pharmacol (1980) 1.02
Measurement of tumor oxygenation: in vivo comparison of a luminescence fiber-optic sensor and a polarographic electrode in the p22 tumor. Radiat Res (2001) 1.02
The effect of microsomal enzyme inhibition on the immunosuppressive and toxic effects of cyclophosphamide. Clin Exp Immunol (1973) 1.01
Enhancement by electron-affinic agents of the therapeutic effects of cytotoxic agents against the KHT tumor: structure-activity relationships. Int J Radiat Oncol Biol Phys (1982) 1.01
DT-diaphorase protects cells from the hypoxic cytotoxicity of indoloquinone EO9. Br J Cancer (1994) 1.00
Clinical anticancer drug development: targeting the cyclin-dependent kinases. Br J Cancer (2005) 0.99
Enzymology of the reductive bioactivation of SR 4233. A novel benzotriazine di-N-oxide hypoxic cell cytotoxin. Biochem Pharmacol (1990) 0.99
Quantitative angiogenesis assays in vivo--a review. Angiogenesis (2004) 0.99
Spontaneous calcification in hearts of DBA mice. Anat Rec (1969) 0.99
Preclinical antitumor activity and pharmacodynamic studies with the farnesyl protein transferase inhibitor R115777 in human breast cancer. Clin Cancer Res (2001) 0.99
Demonstration of tumor-selective retention of fluorinated nitroimidazole probes by 19F magnetic resonance spectroscopy in vivo. Int J Radiat Oncol Biol Phys (1989) 0.99
The role of cytochrome P450 and cytochrome P450 reductase in the reductive bioactivation of the novel benzotriazine di-N-oxide hypoxic cytotoxin 3-amino-1,2,4-benzotriazine-1,4-dioxide (SR 4233, WIN 59075) by mouse liver. Biochem Pharmacol (1992) 0.98
Structure/activity relationships for the enhancement by electron-affinic drugs of the anti-tumour effect of CCNU. Br J Cancer (1982) 0.98
Influence of site on the chemosensitivity of transplantable murine colon tumours to flavone acetic acid (LM975, NSC 347512). Cancer Chemother Pharmacol (1989) 0.98
Preclinical in vitro and in vivo activity of 5,6-dimethylxanthenone-4-acetic acid. Br J Cancer (1995) 0.97
A fluorescence polarization assay for inhibitors of Hsp90. Anal Biochem (2006) 0.96
Effect of misonidazole or metronidazole pretreatment on the response of the RIF-1 mouse sarcoma to melphalan, cyclophosphamide, chlorambucil and CCNU. Br J Cancer (1982) 0.96
Catalytic properties of NAD(P)H:quinone acceptor oxidoreductase: study involving mouse, rat, human, and mouse-rat chimeric enzymes. Mol Pharmacol (1995) 0.96
The sensitivity to chemotherapeutic agents of a rat tumour grown in immunosuppressed mice. Br J Cancer (1971) 0.95
Normalisation of anti-cancer drug dosage using body weight and surface area: is it worthwhile? A review of theoretical and practical considerations. Cancer Chemother Pharmacol (1993) 0.95
Identification of anthracyclines and related agents that retain preferential activity over adriamycin in multidrug-resistant cell lines, and further resistance modification by verapamil and cyclosporin A. Cancer Chemother Pharmacol (1989) 0.94
Establishment and characterisation of new cell lines from human breast tumours initially established as tumour xenografts in NMRI nude mice. Breast Cancer Res Treat (1997) 0.94
Phospholipid antitumor agents. Med Res Rev (1995) 0.93
Relative importance of DT-diaphorase and hypoxia in the bioactivation of EO9 by human lung tumor cell lines. Int J Radiat Oncol Biol Phys (1994) 0.93
Preclinical pharmacokinetics of benznidazole. Br J Cancer (1984) 0.93
EO9: relationship between DT-diaphorase levels and response in vitro and in vivo. Br J Cancer (1995) 0.93
Telomerase activity in normal and malignant mammalian tissues: feasibility of telomerase as a target for cancer chemotherapy. Br J Cancer (1997) 0.93
Initial characterization of the major mouse cytochrome P450 enzymes involved in the reductive metabolism of the hypoxic cytotoxin 3-amino-1,2,4-benzotriazine-1,4-di-N-oxide (tirapazamine, SR 4233, WIN 59075). Biochem Pharmacol (1993) 0.92
Nitroimidazole bioreductive metabolism. Quantitation and characterisation of mouse tissue benznidazole nitroreductases in vivo and in vitro. Biochem Pharmacol (1987) 0.92